Get the Stockscreener App
0.9213
3.02%
-0.0287
After Hours:
.94
0.0187
+2.03%
Bluejay Diagnostics Inc stock is traded at $0.9213, with a volume of 284.26K.
It is down -3.02% in the last 24 hours and up +0.56% over the past month.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
See More
Previous Close:
$0.95
Open:
$0.95054
24h Volume:
284.26K
Relative Volume:
0.06
Market Cap:
$953.28K
Revenue:
-
Net Income/Loss:
$-6.90M
P/E Ratio:
-0.0657
EPS:
-14.0152
Net Cash Flow:
$-6.65M
1W Performance:
+0.14%
1M Performance:
+0.56%
6M Performance:
-52.51%
1Y Performance:
-85.24%
1-Day Range:
$0.91
$0.96
1-Week Range:
$0.8999
$1.03
52-Week Range:
$0.8002
$16.68
Bluejay Diagnostics Inc Stock (BJDX) Company Profile
Name
Bluejay Diagnostics Inc
Sector
Industry
Phone
(978) 631-0152
Address
360 MASSACHUSETTS AVENUE, SUITE 203, ACTON
Compare BJDX vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BJDX
Bluejay Diagnostics Inc
|
0.9213 | 953.28K | 0 | -6.90M | -6.65M | -14.02 |
ABT
Abbott Laboratories
|
101.29 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.64 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.36 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.92 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.29 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bluejay Diagnostics Inc Stock (BJDX) Latest News
Bluejay Diagnostics Inc (NYSE: BJDX) Stock Price, News & Analysis - kalkine.com.au
Bluejay Diagnostics (BJDX) Slips 1.94% to $1.01 as Micro-Cap Diagnostics Stock Tests Key SupportDonchian Channel - siam.in
Monday's Gap-Up and Gap-Down Stock Movers: September 8 - ChartMill
Bluejay Diagnostics expands federal access via Lovell partnership - TipRanks
Bluejay Diagnostics Taps Lovell Government Services as Exclusive SDVOSB Distributor for U.S. Government - TradingView
Bluejay Diagnostics Federal Healthcare Partnership Builds Commercial Pathway Ahead of FDA Clearance - Yahoo Finance
Premarket Movers for Sept. 8, 2026: Notable Gainers and Losers - ChartMill
BJDX Stock Gains Momentum On Sepsis Trial, Cash Boost - timothysykes.com
BJDX Stock Draws Traders As Trial, Cash Runway And 13G Align - StocksToTrade
These stocks are moving in today's pre-market session - ChartMill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
BJDX Stock Draws Traders As Cash, Trial And 13G Align - StocksToTrade
Bluejay Diagnostics, Inc. and Lovell Government Services, Inc. Announce Partnership to Expand Access to U.S. Federal Healthcare Markets - marketscreener.com
Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets - marketscreener.com
A medical test company is preparing for about 170 VA medical centers. FDA clearance or authorization comes first. - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
NASDAQ Stocks Under $1: FNGR, DUO, EPOW, CYAB in Focus Now! - FinancialContent
BJDX Stock Draws Traders As Sepsis Test Milestones Hit - StocksToTrade
Armistice Capital Acquires 142,728 Shares of Bluejay Diagnostics Inc (BJDX) - GuruFocus
Bluejay (BJDX) Session-Level Review: Loses 4.90% to Close at $0.97 at the Close; Reference Levels: the Session Ends Within the Reported Technical Boundaries for the Current SessionGrowth ETF - vinanet.vn
Bluejay Diagnostics (BJDX) links director options to FDA nod - Stock Titan
Bluejay Diagnostics (BJDX) links director’s 100K options to FDA clearance - Stock Titan
Bluejay Diagnostics (BJDX) ties director’s options to FDA device clearance - Stock Titan
Bluejay Diagnostics (NASDAQ: BJDX) insider updates share holdings - Stock Titan
Bluejay Diagnostics (NASDAQ: BJDX) ties director options to FDA clearance - Stock Titan
Bluejay (BJDX) Session-Level Review: Loses 4.90% to Close at $0.97 at the Close; Reference Levels - careplusvn.com
Armistice Capital discloses 9.99% Bluejay Diagnostics (BJDX) position in Schedule 13G - Stock Titan
Bluejay Diagnostics (BJDX) investor group discloses 9.99% ownership with warrants - Stock Titan
Form 8K Bluejay Diagnostics Inc For: 13 August By Investing.com - Investing.com Nigeria
Bluejay Advances Symphony Platform, Strengthens Cash Position - TipRanks
Form 8K Bluejay Diagnostics Inc For: 13 August - Investing.com India
Bluejay Diagnostics Q2 Results: EPS loss narrows 80% YoY to $(1.12) - scanx.trade
Bluejay Diagnostics completes enrollment in sepsis test study - Investing.com
Bluejay Diagnostics completes enrollment in sepsis test study By Investing.com - Investing.com Australia
Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization - The Manila Times
Bluejay Diagnostics Completes Enrollment in SYMON-II Pivotal Study, Advances Toward 510(k) Submission and Commercialization - quiverquant.com
Bluejay completes 750-patient study enrollment for Symphony IL-6 - Stock Titan
Bluejay Diagnostics, Inc. Q2 2026: Net loss $(2.32M), EPS $(1.12) — 10-Q Summary - TradingView
Bluejay Diagnostics (BJDX) warns on going concern and Nasdaq listing risk - Stock Titan
BJDX Forecast & Price Target - TradingKey
Bluejay Diagnostics Inc (BJDX) Stock News Today - tradingkey.com
Why Are Traders Watching Bluejay Diagnostics (NASDAQ:BJDX) This Week? - Kalkine Media
Bullish Volume: RITR, IGC, BJDX, CISS Lead Active Sub-$1 Stocks to Watch - Barchart.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
BJDX Stock Dips As Pivotal Sepsis Study Finishes Early - StocksToTrade
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
BJDX Stock Dips As Pivotal Sepsis Trial Finishes Enrollment Early - StocksToTrade
Bluejay Diagnostics (NASDAQ:BJDX) soars 47% premarket; warrant financing still subject to conditions - TechStock²
Trending Stocks Today | Julong Soars 42.47% Pre-Market - Moomoo
Ready for the party🤓 - Moomoo
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Bluejay Diagnostics Inc Stock (BJDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
0.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):